Topotecan

DB01030ApprovedInvestigationalSmall moleculeTopoisomerase Inhibitors

Topotecan is an antineoplastic agent used to treat ovarian cancer, small cell lung cancer, or cervical cancer. It works by inhibiting DNA topoisomerases, type I.

Chemical structure of Topotecan
Mechanism
Curator reviewed
Primary indication
For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens.Curator reviewed · 9 structured indications
Formula / weight
C23H23N3O5 · 421.4458 g/mol (avg)
First approval
Canada, 2009 · United States, 1996 · European Union, 2016
Also known as
hycamptamine
Code names
SK&F-104864 · SKF S-104864-A
Brand names
  • Hycamtin

Resolves to

Structure
InChIKeyUCFGDBYHRUNTLO-QHCPKHFHSA-NSMILESCC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
4TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,507Drug interactionsStructured to mechanism, not free text
Sign in
345Clinical trialsPhase, status and sponsor resolved per trial
Sign in
9Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
154Marketed productsAcross 10 countries and 45 labellers
Sign in
1ATC codeIncluding every combination product, plus 24 drug categories
Sign in
38+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Topotecan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account